| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.01 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A farmacovigilância constitui um pilar essencial da segurança do medicamento, sendo as medidas adicionais de minimização de risco (MMRa) fundamentais quando as de rotina se revelam insuficientes. Os medicamentos contendo valproato, devido à sua teratogenicidade, estão sujeitos a várias MMRa como o Programa de Prevenção da Gravidez. O farmacêutico comunitário, enquanto último profissional de saúde em contacto com o utente antes do início da terapêutica, desempenha um papel fundamental na sua efetividade. Este estudo teve como objetivo avaliar os conhecimentos e atitudes dos farmacêuticos comunitários relativamente às MMRa dos medicamentos contendo valproato. Foi conduzido um estudo observacional, transversal, com recurso a um questionário online dirigido a farmacêuticos de farmácias filiadas da Associação Nacional das Farmácias (ANF). A amostra final incluiu 196 farmacêuticos das diferentes regiões do país. Os resultados mostram que 90,8% conhecem as MMRa, sendo a rotulagem/embalagem especial (75,5%) e as Comunicações dirigidas aos Profissionais de Saúde (65,8%) as mais conhecidas. Contudo, apenas 38,3% conhece o Programa de Prevenção da Gravidez e 29,2% as medidas destinadas a homens em idade fértil. Ainda existem 11,7% de farmacêuticos que não utilizam qualquer medida no ato de dispensa, alegando principalmente desconhecimento e dificuldade de acesso. Relativamente às atitudes na dispensa, 80,6% aconselha sobre contraceção eficaz e 77,6% referenciam para consulta médica em caso de suspeita de gravidez, embora 9,2% não presta qualquer aconselhamento. Os farmacêuticos comunitários revelam elevado conhecimento global, mas persistem lacunas em medidas específicas e recentes. O reforço formativo e a integração de alertas nos sistemas informáticos poderão aumentar a adesão às MMRa e garantir o uso seguro dos medicamentos.
Pharmacovigilance is a cornerstone of drug safety, with additional risk minimization measures (aRMM) being essential whenever routine strategies prove insufficient. Valproate-containing medicines, due to their teratogenicity, are subject to several aRMM, such as the Pregnancy Prevention Programme. Community pharmacists, as the last healthcare professionals in contact with patients before starting therapy, play a crucial role in their effectiveness. This study aimed to assess the knowledge and attitudes of community pharmacists regarding the aRMM of valproate-containing medicines. An observational, cross-sectional study was conducted using an online questionnaire distributed to pharmacists working in pharmacies affiliated with the National Association of Pharmacies. The final sample included 196 pharmacists from different regions of the country. Results show that 90.8% are aware of aRMM, with special labelling/packaging (75,5%) and Direct Healthcare Professional Communications (65,8%) being the most recognized. However, only 38,3% are aware of the Pregnancy Prevention Programme and 29,2% of the measures targeted at men of reproductive age. Moreover, 11,7% of pharmacists reported not using any measure during dispensing, mainly due to lack of awareness or difficult access. Regarding attitudes during dispensing, 80,6% advise on effective contraception and 77,6% refer patients to medical consultation in case of suspected pregnancy, although 9,2% provide no counselling. Community pharmacists demonstrate a high overall level of knowledge, but gaps remain regarding specific and recent measures. Strengthening training and integrating alerts into pharmacy software systems may improve adherence to aRMM and ensure the safe use of these medicines.
Pharmacovigilance is a cornerstone of drug safety, with additional risk minimization measures (aRMM) being essential whenever routine strategies prove insufficient. Valproate-containing medicines, due to their teratogenicity, are subject to several aRMM, such as the Pregnancy Prevention Programme. Community pharmacists, as the last healthcare professionals in contact with patients before starting therapy, play a crucial role in their effectiveness. This study aimed to assess the knowledge and attitudes of community pharmacists regarding the aRMM of valproate-containing medicines. An observational, cross-sectional study was conducted using an online questionnaire distributed to pharmacists working in pharmacies affiliated with the National Association of Pharmacies. The final sample included 196 pharmacists from different regions of the country. Results show that 90.8% are aware of aRMM, with special labelling/packaging (75,5%) and Direct Healthcare Professional Communications (65,8%) being the most recognized. However, only 38,3% are aware of the Pregnancy Prevention Programme and 29,2% of the measures targeted at men of reproductive age. Moreover, 11,7% of pharmacists reported not using any measure during dispensing, mainly due to lack of awareness or difficult access. Regarding attitudes during dispensing, 80,6% advise on effective contraception and 77,6% refer patients to medical consultation in case of suspected pregnancy, although 9,2% provide no counselling. Community pharmacists demonstrate a high overall level of knowledge, but gaps remain regarding specific and recent measures. Strengthening training and integrating alerts into pharmacy software systems may improve adherence to aRMM and ensure the safe use of these medicines.
Descrição
Palavras-chave
Farmacovigilância MMRa Valproato Farmacêutico comunitário Conhecimento Atitude